Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10626157 | 0.78 | RAPGEF4 (0.60) | RAPGEF4 | |
| SCHEMBL1305358 | 0.75 | CYP3A4 (0.52) | RAPGEF4TTR | |
| SCHEMBL16172587 | 0.74 | HTR1D (0.40) | RAPGEF4 | |
| SCHEMBL12379160 | 0.74 | TTR (0.40) | RAPGEF4TTR | |
| SCHEMBL18619506 | 0.70 | TRPM8 (0.34) | RAPGEF4 | |
| SCHEMBL31424463 | 0.70 | RAPGEF4 (0.33) | RAPGEF4 | |
| SCHEMBL15434937 | 0.67 | TTR (0.40) | TTR | |
| SCHEMBL17481117 | 0.67 | TTR (0.40) | TTR | |
| SCHEMBL27942651 | 0.67 | ALDH1A1 (0.43) | — | |
| SCHEMBL27045679 | 0.64 | FFAR4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481546-B2 | CGRP receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120059017-A1 | CGRP Receptor Antagonist | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059017-A1 | CGRP Receptor Antagonist | CALCRL, PTGIR, CALCR | RAPGEF4 1774/4885TTR 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.